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Allergic rhinitis is a real problem for public health insofar
as it generally affects young and economically active 
subjects, whose quality of life is altered. The WHO has
ranked it sixth in its concerns. The cost of chronic aller-
gic rhinitis are largely underestimated, as its symptoms
are obviously less spectacular than those of asthma.
Mostly, rhinitis precedes asthma. The latter is at least four
times more common in people who suffer from rhinitis
than the general population. OBJECTIVE: The objective
is to compare the average cost of treatment of rhinitis 
in adults depending on whether the patient is treated
homoeopathically or allopathically. METHOD: Prospec-
tive and longitudinal observational programme carried
out among general practitioners in the context of their
everyday work. RESULTS: The costs were added together
over the three months and expressed in Euros. They are
the result of the value of the resources used, and itemized
by the doctor researching. The perspective adopted was
the same as that of society in general, which is global and
the largest as it does not refer to any system of reim-
bursement. Within this perspective, valorisation of costs
is calculated according to an evaluation of opportunity
costs. In practice, one should know that opportunity cost
is complex and a great number of authors use approxi-
mations based on market values (e.g. salary). The cost 
of treatment for 3 months (society’s perspective) for the
group treated allopathically (€45) is 40% more expensive
than the homeopathic treatment (€27), CONCLUSION:
The preliminary results of this study (after 3 months),
reveal the pertinence of the homeopathic treatment was
made clear by a cost 40% cheaper than the group treated
allopathically.
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OBJECTIVES: To describe the prevalence and cumulative
incidence of allergic conjunctivitis (AC) in the United
Kingdom population. A secondary aim was to describe
the treatment pattern of AC with reference to the type
and duration of therapeutic treatments used, the type and
frequency of referrals to hospital and medical specialists,
and the frequency of tests performed. Setting: A retro-
spective review of administrative database containing
information on general practitioners collected in the
United Kingdom. METHODS: The Full Feature General
Practice Research Database (FF-GPRD) of the UK Med-
icines Control Agency, Department of Health, UK a com-
puterized database of anonymized longitudinal clinical
records from general practices throughout the UK was
accessed for this study. The study cohort consisted of all
patients in FF-GPRD with a record of either diagnosis or
topical eye treatment of AC (deﬁned as either: conjunc-
tivitis; keratoconjunctivitis; vernal keratoconjunctivitis;
or other additional AC terminology during the study
period 1990–2000). RESULTS: During the study period
(1990–2000) 350,119 subjects with AC were identiﬁed.
A total of 299,133 cases were identiﬁed by a Medical
term for AC; 50,986 cases were identiﬁed by a prescrip-
tion for topical eye therapy. The age-standardised cum-
mulative incidence (CI) and prevalence (P) of AC in 2000
amongst the at-risk population covered by the GPRD
database was CI = 18.4 and P = 33.1 per 1000, respec-
tively. Counts of distinct individuals exposed to topical
or systemic treatment resulted in 64,470, and 8,388
patients, respectively. Lastly out of a total of 112,424
treatment episodes of AC patients exposed to either
topical and/or systemic treatment during the entire
period, 102,948 (91.4 %) were of less than 30 days dura-
tion, while 9476 (8.4 %) were greater than 30 days in
duration. CONCLUSIONS: Allergic conjunctivitis is a
highly prevalent chronic condition in the UK and is asso-
ciated with a high frequency of topical and systemic med-
ication usage.
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